These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 7028944)

  • 1. Therapy for urolithiasis with hydroxamic acids. IV. Prevention of infected urinary stone formation with N-(pivaloyl)glycinohydroxamic acid.
    Satoh M; Munakata K; Kitoh K; Seto N; Kanazawa T; Takeuchi H; Yoshida O
    J Pharmacobiodyn; 1981 Jul; 4(7):469-74. PubMed ID: 7028944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of infected urinary stones in rats by a new hydroxamic acid, "N-(pivaloyl)glycinohydroxamic acid.
    Takeuchi H; Okada Y; Kobashi K; Yoshida O
    Urol Res; 1982; 10(4):217-9. PubMed ID: 6758273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of infected urinary stones in rats by urease inhibitor: a new hydroxamic acid derivative.
    Takeuchi H; Kobashi K; Yoshida O
    Invest Urol; 1980 Sep; 18(2):102-5. PubMed ID: 6997228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prevention of infected urinary stones by urease inhibitor. IV. Treatment of infection stones in rats by a new hydroxamic acid and cefalexin].
    Takeuchi H; Tomoyoshi T; Okada Y; Yoshida O; Kobashi K
    Hinyokika Kiyo; 1983 Mar; 29(3):297-302. PubMed ID: 6375315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of effects of novel urease inhibitor, N-(pivaloyl)glycinohydroxamic acid on the formation of an infection bladder stone using a newly designed urolithiasis model in rats.
    Satoh M; Munakata K; Takeuchi H; Yoshida O; Takebe S; Kobashi K
    Chem Pharm Bull (Tokyo); 1991 Apr; 39(4):894-6. PubMed ID: 1893494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapy for urolithiasis by hydroxamic acids. III. Urease inhibitory potency and urinary excretion rate of N-acylglycinohydroxamic acids.
    Munakata K; Kobashi K; Takebe S; Hase J
    J Pharmacobiodyn; 1980 Sep; 3(9):451-6. PubMed ID: 7007614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapy for urolithiasis by hydroxamic acids. II. Urease inhibitory potency and urinary excretion rate of hippurohydroxamic acid derivatives.
    Kobashi K; Munakata K; Takebe S; Hase J
    J Pharmacobiodyn; 1980 Sep; 3(9):444-50. PubMed ID: 7007613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benurestat, a urease inhibitor for the therapy of infected ureolysis.
    Andersen JA
    Invest Urol; 1975 Mar; 12(5):381-6. PubMed ID: 1089613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Urinary calculi and infection].
    Trinchieri A
    Urologia; 2014; 81(2):93-8. PubMed ID: 24874306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Computerized in vivo research from the growth of urease-producing bacteria in the presence of antibiotics combined with propionhydroxamic acid.
    Rizzo M; Nicoletti P; Bartoletti R; Luciani E
    Contrib Nephrol; 1987; 58():219-21. PubMed ID: 3319403
    [No Abstract]   [Full Text] [Related]  

  • 11. Prevention of infected urinary stones by urease inhibition.
    Griffith DP; Musher DM
    Invest Urol; 1973 Nov; 11(3):228-33. PubMed ID: 4584162
    [No Abstract]   [Full Text] [Related]  

  • 12. Inhibition of bacterial urease.
    Griffith DP; Musher DM; Campbell JW
    Invest Urol; 1973 Nov; 11(3):234-8. PubMed ID: 4201416
    [No Abstract]   [Full Text] [Related]  

  • 13. Stone formation by Ureaplasma urealyticum in human urine and its prevention by urease inhibitors.
    Takebe S; Numata A; Kobashi K
    J Clin Microbiol; 1984 Nov; 20(5):869-73. PubMed ID: 6549013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of urease in pyelonephritis resulting from urinary tract infection with Proteus.
    Musher DM; Griffith DP; Yawn D; Rossen RD
    J Infect Dis; 1975 Feb; 131(2):177-81. PubMed ID: 234993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of crystallization caused by Proteus mirabilis during the development of infectious urolithiasis by various phenolic substances.
    Torzewska A; Rozalski A
    Microbiol Res; 2014; 169(7-8):579-84. PubMed ID: 24239192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccines for Proteus mirabilis in urinary tract infection.
    Li X; Mobley HL
    Int J Antimicrob Agents; 2002 Jun; 19(6):461-5. PubMed ID: 12135833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ureaplasma urealyticum-induced crystallization of magnesium ammonium phosphate and calcium phosphates in synthetic urine.
    Grenabo L; Brorson JE; Hedelin H; Pettersson S
    J Urol; 1984 Oct; 132(4):795-9. PubMed ID: 6381769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deacidification by FhlA-dependent hydrogenase is involved in urease activity and urinary stone formation in uropathogenic Proteus mirabilis.
    Lin WY; Liaw SJ
    Sci Rep; 2020 Nov; 10(1):19546. PubMed ID: 33177598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of acetohydroxamic acid on the induction of bacterial ureases.
    Rosenstein I; Hamilton-Miller JM; Brumfitt W
    Invest Urol; 1980 Sep; 18(2):112-4. PubMed ID: 6997229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Acetylhydroxamic acid in the treatment of nephrolithiasis, caused by infection with urease forming microorganisms].
    Lorenz J; Lorenz K; Dabrowska B; Kowal R
    Z Urol Nephrol; 1989 Dec; 82(12):685-9. PubMed ID: 2698024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.